News Daily News Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS Michael O'Riordan December 30, 2022
News Daily News Anatomic Disease After PCI Linked With Worse Outcomes: VA CART Michael O'Riordan December 22, 2022
News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Daily News mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events Michael O'Riordan September 26, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022
News Daily News FDA Approves Empagliflozin for Treatment of HFpEF Michael O'Riordan February 24, 2022